YS Biopharma (Summit Healthcare Acquisition) ^{Priced, Nasdaq: YS}

We are a newly incorporated blank check company. Bo Tan, our Chief Executive Officer and Co-Chief Investment Officer, has over 20 years of extensive experience in the financial and pharmaceutical industries and was the President and Chief Financial Officer of 3S Bio. Ken Poon, our President and Co-Chief Investment Officer, has nearly 30 years of capital markets experiences in Asia and is the founding partner of XCap Partners Limited, a boutique advisory firm in Hong Kong. We intend to focus on potential acquisition targets in the healthcare industry. While we may acquire a business in any region globally, we will focus on finding an asset with a strong China nexus. We believe the healthcare sector in Asia has historically benefited from the in-licensing of novel or differentiated therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. Today, we are witnessing the rise of healthcare out-licensing from China, a phenomenon that creates a 'two-way' traffic that brings significant benefits to patients in both China and Western countries. Our management team has demonstrated a strong track record of creating significant shareholder values at healthcare companies across the various stages of development. Leveraging on our broad network, deep industry insights, exceptional operational expertise and proven deal execution, we believe our team has the relevant skills and experiences to generate significant shareholder value.